Última atualização: Agosto 17, 2026

Stem cell transplantation has emerged as a promising strategy to treat a variety of diseases, including hematologic malignancies. No entanto, doença do enxerto contra hospedeiro (GvHD) remains a major complication associated with stem cell transplantation. GvHD occurs when donor immune cells attack the recipient’s healthy tissues, leading to inflammation and organ damage.
Transplante de células-tronco: A Promising Strategy

Stem cell transplantation involves the transfer of healthy stem cells from a donor to a recipient. These stem cells can differentiate into various cell types, incluindo células imunológicas, which can help to restore the recipient’s immune system. Stem cell transplantation has been used to successfully treat a variety of hematologic malignancies, incluindo leucemia, linfoma, e mieloma.
Immunomodulatory Potential of Stem Cells

Stem cells have immunomodulatory properties that can help to prevent or treat GvHD. These properties include the ability to:

  1. Suppress the activation of donor immune cells: Stem cells can release factors that inhibit the activation of donor immune cells, thereby reducing the risk of GvHD.
  2. Promote the development of regulatory immune cells: Stem cells can promote the development of regulatory immune cells, which help to control the immune response and prevent excessive inflammation.

Stem cell-based approaches hold great promise for overcoming GvHD and improving the outcomes of stem cell transplantation. Further research is needed to develop and refine these approaches, but they have the potential to revolutionize the treatment of hematologic malignancies.

Evidência Científica

Research in stem cells and cellular technologies continues to develop across regenerative medicine, immunology and tissue repair. The strength of evidence differs considerably between cell types, medical conditions and treatment protocols. Laboratory findings, early clinical studies and established therapeutic applications should therefore be evaluated separately. Any clinical decision should be based on the patient’s diagnosis, current medical status, available evidence and the regulatory framework applicable in the country of treatment.

Extracellular Vesicles and Exosomes

Extracellular vesicles, including populations commonly described as exosomes, are being investigated as mediators of intercellular communication and paracrine activity. Their biological properties depend on the source cells, isolation method, caracterização, concentration and storage conditions. Measurements expressed only as particle numbers do not provide a complete assessment of identity, purity or potency. Clinical claims should therefore be distinguished carefully from laboratory research and early-stage clinical evidence.

Extracellular Vesicles and Exosomes

Extracellular vesicles, including populations commonly described as exosomes, are being investigated as mediators of intercellular communication and paracrine activity. Their biological properties depend on the source cells, isolation method, caracterização, concentration and storage conditions. Measurements expressed only as particle numbers do not provide a complete assessment of identity, purity or potency. Clinical claims should therefore be distinguished carefully from laboratory research and early-stage clinical evidence.

Revisão de caso científico

Revisão de Caso Científico

Você gostaria de entender se os programas clínicos atuais, desenvolvimentos de pesquisa recentes, ou abordagens emergentes podem ser relevante para sua situação individual?

Compartilhe sua dúvida com nossa equipe de pesquisa científica e receba informações focadas nas áreas de pesquisa atual que podem ser relevante para o seu caso.

  • Revisão das informações que você fornece
  • Informações relevantes sobre pesquisas e programas clínicos
  • Uma resposta clara focada na sua situação
O que acontece a seguir? Envie sua pergunta, receber uma revisão científica focada, e obter uma resposta clara sobre pesquisas e programas clínicos relevantes para sua situação.
Sua revisão científica será preparada por Dr.. Helen Melnik, Doutorado , quem tem mais de 25 anos de experiência em pesquisa com células-tronco e programas clínicos internacionais.

Sem obrigação. Sua pergunta será analisada confidencialmente.

Apenas informações educacionais e de pesquisa. Este serviço não constituem aconselhamento médico, diagnóstico, prescrição, ou um personalizado recomendação de tratamento.

Categorias: Bronquite Crônica AVCMercado de células-troncoterapias com células-troncoTerapia com células-troncoTerapia com células-tronco & Pesquisa ClínicaEnsaios clínicos com células-troncoterapia com células-troncoTerapia com células-tronco da paralisia cerebraltratamento com células-troncotratamento com células-tronco na Ucrâniaalerta sobre células-troncocirurgia

NBSciência

organização de pesquisa contratada

WhatsApp